March 6, 2018 04:41 PM EST

Metavant makes a debut: Vivek Ramaswamy launches biotech #7 and builds a diabetes pipeline with Ligand deal

John Carroll

Editor & Founder

Just because David Hung recently left one of Vivek Ramaswamy’s Vant subsidiaries shortly after its lead therapy imploded in a failed pivotal study for Alzheimer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Metavant makes a debut: Vivek Ramaswamy launches biotech #7 and builds a diabetes pipeline with Ligand deal

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Outlook's shares crash as wet AMD drug flunks Phase 3 test

Meta­vant makes a de­but: Vivek Ra­maswamy launch­es biotech #7 and builds a di­a­betes pipeline with Lig­and deal

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Metavant makes a debut: Vivek Ramaswamy launches biotech #7 and builds a diabetes pipeline with Ligand deal

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Outlook's shares crash as wet AMD drug flunks Phase 3 test